![](/wp-content/uploads/2023/08/Screenshot-2023-08-30-at-3.19.49-PM.png)
$599
Novo to Acquire Another Obesity Company; Zealand Receives Priority Review for Dasiglucagon CHI NDA
Two cardiometabolic-related news items have been observed: Embark Laboratories announced that Novo Nordisk acquired the company and its lead obesity asset (view press release); and Zealand announced FDA granted priority review for its dasiglucagon NDA for the prevention and treatment of hypoglycemia in pediatric patients 7 days of age or older with congenital hyperinsulinism (CHI; view press release). Below, FENIX provides highlights and insights for the respective news items.